SEC Company Response from INSMED Inc (INSM) (CIK 0001104506) (INSM) — Jan 21, 2020
INSMED Inc (INSM) (CIK 0001104506)
Date: Jan. 21, 2020 · CIK: 0001104506 · Accession: 0001104659-20-005536
AI Filing Summary & Sentiment
File numbers found in text: 000-30739
Referenced dates: December 4, 2019
Letter
700 US Highway 202/206
Bridgewater, New Jersey 08807
Phone: (908) 977-9900
www.insmed.com
VIA EDGAR
January 21, 2020
U.S. Securities and Exchange Commission (the “Commission”)
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Ameen Hamady
Ms. Jeanne Baker
Re: INSMED Inc
Form 10-K filed on February 22, 2019
Form 8-K filed on October 30, 2019
File no. 000-30739
Ladies and Gentlemen:
Insmed Incorporated (the “Company”) respectfully submits this letter in response to a letter, dated January 14, 2020, from the staff of the Commission (the “Staff”) commenting on the Company’s Current Report on Form 8-K filed with the Commission on October 30, 2019. To facilitate the Staff’s review, we have included in this letter the caption and comment from the Staff’s letter in bold text and the Company’s response immediately thereafter.
Form 8-K filed on October 30, 2019
Exhibit 99.1
Non-GAAP Financial Measures, page 3
1. We note your response to our comment from our letter dated December 4, 2019. In order to distinguish your Arikayce milestone payments from your other more typical milestone payments, please expand your disclosures to highlight the nature of your research funding arrangement with the Cystic Fibrosis Foundation and how the arrangement differs from your other license agreements.
Response:
The Company acknowledges the Staff’s comment and intends to expand its future disclosure to highlight the nature of its research funding arrangement with Cystic Fibrosis Foundation Therapeutics, Inc. and how it differs from the Company’s license agreements.
* * * * *
Correspondence regarding this letter may be directed to the attention of the undersigned at john.goll@insmed.com. In addition, you may contact me at (732) 487-7395 or Christine Pellizzari at (732) 487-7366.
Sincerely,
INSMED INCORPORATED
Show Raw Text
CORRESP 1 filename1.htm 700 US Highway 202/206 Bridgewater, New Jersey 08807 Phone: (908) 977-9900 www.insmed.com VIA EDGAR January 21, 2020 U.S. Securities and Exchange Commission (the “Commission”) Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Ameen Hamady Ms. Jeanne Baker Re: INSMED Inc Form 10-K filed on February 22, 2019 Form 8-K filed on October 30, 2019 File no. 000-30739 Ladies and Gentlemen: Insmed Incorporated (the “Company”) respectfully submits this letter in response to a letter, dated January 14, 2020, from the staff of the Commission (the “Staff”) commenting on the Company’s Current Report on Form 8-K filed with the Commission on October 30, 2019. To facilitate the Staff’s review, we have included in this letter the caption and comment from the Staff’s letter in bold text and the Company’s response immediately thereafter. Form 8-K filed on October 30, 2019 Exhibit 99.1 Non-GAAP Financial Measures, page 3 1. We note your response to our comment from our letter dated December 4, 2019. In order to distinguish your Arikayce milestone payments from your other more typical milestone payments, please expand your disclosures to highlight the nature of your research funding arrangement with the Cystic Fibrosis Foundation and how the arrangement differs from your other license agreements. Response: The Company acknowledges the Staff’s comment and intends to expand its future disclosure to highlight the nature of its research funding arrangement with Cystic Fibrosis Foundation Therapeutics, Inc. and how it differs from the Company’s license agreements. * * * * * Correspondence regarding this letter may be directed to the attention of the undersigned at john.goll@insmed.com. In addition, you may contact me at (732) 487-7395 or Christine Pellizzari at (732) 487-7366. Sincerely, INSMED INCORPORATED /s/ John Goll John Goll Chief Accounting Officer cc: Christine Pellizzari, Insmed Incorporated Michael J. Riella, Covington & Burling LLP 2